Real-world andexanet alfa utilization and the association between delay in administration due to hospital transfer and all-cause inpatient mortality
Background: Evaluations of andexanet alfa for the reversal of factor Xa inhibitor-associated bleeding have been small, with cohorts drawn from single/limited sites. Delays in providing anticoagulation reversal due to hospital transfer may result in poorer outcomes. Objectives: To describe the charac...
Saved in:
| Main Authors: | Huiqiao Fan, Youssef Bessada, Craig I. Coleman |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Research and Practice in Thrombosis and Haemostasis |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2475037925000123 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Management of factor Xa inhibitor–related traumatic non‐intracranial bleeding events with andexanet alfa or four‐factor prothrombin complex concentrate in a US multicenter observational study
by: Paul P. Dobesh, et al.
Published: (2024-12-01) -
Andexanet alfa: trials just leave us with more questions
by: Richard J. Buka
Published: (2025-01-01) -
Definition of factor Xa inhibitor–related, life‐threatening gastrointestinal bleeding and guidance on when to use reversal therapy: A Delphi panel
by: Gregory J. Fermann, et al.
Published: (2023-10-01) -
Clinical and health care resource use burden of hospitalizations for oral factor Xa inhibitor‐associated major bleeding: A real‐world analysis of Medicare beneficiaries
by: James M. Williams, et al.
Published: (2023-06-01) -
Ánh xạ cảm sinh trên siêu không gian tích đối xứng cấp n
by: Trần Đức Thanh, et al.
Published: (2024-09-01)